Longitude Capital
SlowingFiled to raiseMenlo Park, CABiotech & pharma, Medical devices, Logistics & supply chainLast fund filed November 2025
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Longitude 103.8 East | November 2025 | $100M | $100M | 1 |
| Longitude Prime Fund II | August 2022 | $200M | $50M | 10 |
| Longitude Venture Partners V | August 2022 | $600M | $207M | 18 |
| Longitude Prime FundFiled to raise in 2021, with no closing reported yet. | 2021 | $130M | $0 | 0 |
| Longitude Venture Partners IV |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Patrick Enright | Slowing | Biotech & pharma, Logistics & supply chain, Real estate & proptech | 18 |
Categories of Longitude Capital’s own portfolio companies, based on 19 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Longitude Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Sofinnova Venture Partners | 3 | BioAge Labs, Venus Concept, Vera Therapeutics |
| Frazier Life Sciences | 2 | Aptinyx, SutroVax |
| Alta Partners | 1 | Esperion Therapeutics |
| Asset Management Ventures |
| 2019 |
| $550M |
| $0 |
| 0 |
| Longitude Venture Partners III | May 2016 | $525M | $525M | 70 |
| 1 |
| Juliet Tammenoms Bakker | Quiet | Medical devices | 2 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 1 |
| CARDIODX |
| Bain Capital Life Sciences | 1 | Aptinyx |
| Foresite | 1 | Allergen Research |
| Healthquest Partners | 1 | Venus Concept |
| Kleiner Perkins | 1 | Vera Therapeutics |
| Medicxi | 1 | Rivus Pharmaceuticals |
| Playground Global | 1 | INFACARE PHARMACEUTICAL |
| Sonder Futures | 1 | Venus Concept |
| Vivo Capital | 1 | Zenas BioPharma (Cayman) |
| Westlake Biopartners | 1 | Vera Therapeutics |
A shared board seat: a company where filings name a Longitude Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.